Rhythm Pharmaceuticals, Inc. (RYTM) News
Filter RYTM News Items
RYTM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RYTM News Highlights
- RYTM's 30 day story count now stands at 4.
- Over the past 9 days, the trend for RYTM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RARE, BMI and DEC are the most mentioned tickers in articles about RYTM.
Latest RYTM News From Around the Web
Below are the latest news stories about RHYTHM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RYTM as an investment opportunity.
Rhythm Pharmaceuticals Announces New Employment Inducement GrantsBOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on December 7, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 10,500 shares of its common stock to o |
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023-- More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases -- -- Approximately 150 healthcare professionals from 20 countries expected to attend -- BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocor |
Insider Sell Alert: CFO Hunter Smith Sells 27,026 Shares of Rhythm Pharmaceuticals Inc (RYTM)In a recent transaction on December 6, 2023, Hunter Smith, the Chief Financial Officer (CFO) of Rhythm Pharmaceuticals Inc, sold a significant number of shares in the company. |
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event-- Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-<6yo (N=12) over 52 weeks achieved primary endpoint -- -- Setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in patients ages 2-<6yo with obesity due to POMC/LEPR deficiency or BBS -- -- RM-718 showed potential to reduce body weight and hyperphagia with no off-target cardiovascular effects and no hyperpigmentation observed in pre-clinical studies; first in-human studies anticipate |
Insider Sell Alert: Joseph Shulman of Rhythm Pharmaceuticals Inc Cashes Out SharesIn the realm of biopharmaceuticals, insider transactions are often scrutinized for insights into the company's health and future prospects. |
Investors ignore increasing losses at Rhythm Pharmaceuticals (NASDAQ:RYTM) as stock jumps 5.1% this past weekBy buying an index fund, you can roughly match the market return with ease. But if you pick the right individual... |
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue EstimatesRhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 0% and 2.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Rhythm Pharmaceuticals Inc (RYTM) Reports Q3 2023 Financial ResultsNet Revenue of $22.5 Million and Cash On-Hand of $299.3 Million |
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update-- Third quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $22.5 million -- -- More than 100 international patients on reimbursed IMCIVREE therapy -- -- Phase 3 hypothalamic obesity trial on track to be fully enrolled by the end of 2023 -- -- 25.5% mean BMI reduction achieved at one year of setmelanotide therapy in patients with hypothalamic obesity (n=12) who transitioned to long term extension from Ph 2 trial; three of 11 pediatric patients achieving normal body weight |
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)-- CADTH recommends reimbursement for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS) -- -- Recommendation based on demonstrated clinical benefit in Phase 3 trial -- BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by |